Company: BWAY
Filing Date: 2025-04-22
Form Type: F-3
Source: 0001171843-25-002378
Chunk: 6

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: F-3
Chunk 6
---
 nor these definitions
have been verified by any independent source.

Unless the context indicates otherwise, the term “selling
shareholder” as used in this prospectus means the selling shareholder referred to in this prospectus and its transferees, pledgees,
donees, assignees and other successors-in-interest.

| i |

Unless the context indicates otherwise,
as used in this prospectus, the terms “BrainsWay,” “we,” “us,” “our,” the “Company”
and similar designations refer to BrainsWay Ltd., a limited liability company incorporated under the laws of the State of Israel, and
its consolidated subsidiaries.

This prospectus and the information incorporated herein
by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade
names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus
are the property of their respective owners. Use or display by us of trademarks, service marks or trade names owned by others is not intended
to and does not imply a relationship between us and, or endorsement or sponsorship by, the owners of the trademarks, service marks or
trade names.

| ii |

<div align='center'>PROSPECTUS SUMMARY</div>

This summary provides an overview of selected information contained elsewhere or incorporated by reference into this prospectus and does not contain all the information you should consider before investing in our securities. You should carefully read the prospectus, any applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading“Risk Factors” contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

<div align='center'>BRAINSWAY LTD.

Overview</div>

We are a global leader in advanced noninvasive neurostimulation
treatments for mental health disorders. We are boldly advancing neuroscience with our proprietary Deep Transcranial Magnetic Stimulation
(Deep TMS™) platform technology to improve health and transform lives. We are dedicated to leading through superior science and
building on what we believe to be an unparalleled body of clinical evidence. We are the first and only TMS company to be cleared by the
FDA for three separate mental health condition indications based on clinically proven efficacy as demonstrated in